Elevance Health (ELV) Cost of Revenue (2009 - 2026)

Elevance Health (ELV) has reported Cost of Revenue for 18 consecutive years, with $5.5 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue fell 85.04% year-over-year to $5.5 billion; the TTM figure through Jun 2026 stood at $117.3 billion (up 526.05% YoY), while the FY2025 annual figure was $148.2 billion, up 650.5% from the prior year.
• Cost of Revenue declined to $5.5 billion in Q2 2026 per ELV's latest filing, from $35.6 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $111.9 billion in Q4 2023 and bottomed at -$74.3 billion in Q4 2024.
• Historically, Cost of Revenue has averaged $20.4 billion across 5 years, with a median of $28.5 billion in 2022.
• Annual changes were most pronounced in 2023 — Cost of Revenue jumped 2968.4% — and 2024, when it sank 166.43%.
• Elevance Health's Cost of Revenue stood at $3.6 billion in 2022, then surged by 2968.4% to $111.9 billion in 2023, then tumbled by 166.43% to -$74.3 billion in 2024, then soared by 151.22% to $38.1 billion in 2025, then sank by 85.57% to $5.5 billion in 2026.
• Business Quant data shows ELV's Cost of Revenue at $5.5 billion in Q2 2026, $35.6 billion in Q1 2026, and $38.1 billion in Q4 2025.